-
1
-
-
1342290189
-
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
-
CrossRef PubMed
-
Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, De Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol. 2004; 22: 229-237. CrossRef PubMed
-
(2004)
J Clin Oncol.
, vol.22
, pp. 229-237
-
-
Tournigand, C.1
André, T.2
Achille, E.3
Lledo, G.4
Flesh, M.5
Mery-Mignard, D.6
Quinaux, E.7
Couteau, C.8
Buyse, M.9
Ganem, G.10
Landi, B.11
Colin, P.12
Louvet, C.13
De Gramont, A.14
-
2
-
-
37249009181
-
Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer
-
CrossRef PubMed
-
Ohyanagi F, Horiike A, Okano Y, Satoh Y, Okumura S, Ishikawa Y, Nakagawa K, Horai T, Nishio M. Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer. Cancer Chemother Pharmacol. 2008; 61: 503-508. CrossRef PubMed
-
(2008)
Cancer Chemother Pharmacol.
, vol.61
, pp. 503-508
-
-
Ohyanagi, F.1
Horiike, A.2
Okano, Y.3
Satoh, Y.4
Okumura, S.5
Ishikawa, Y.6
Nakagawa, K.7
Horai, T.8
Nishio, M.9
-
3
-
-
67449084936
-
Phase i study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study
-
CrossRef PubMed
-
Yamamoto K, Kokawa K, Umesaki N, Nishimura R, Hasegawa K, Konishi I, Saji F, Nishida M, Noguchi H, Takizawa K. Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study. Oncol Rep. 2009; 21: 1005-1009. CrossRef PubMed
-
(2009)
Oncol Rep.
, vol.21
, pp. 1005-1009
-
-
Yamamoto, K.1
Kokawa, K.2
Umesaki, N.3
Nishimura, R.4
Hasegawa, K.5
Konishi, I.6
Saji, F.7
Nishida, M.8
Noguchi, H.9
Takizawa, K.10
-
4
-
-
33847663871
-
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study
-
PubMed
-
Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007; 18: 510-517. PubMed
-
(2007)
Ann Oncol.
, vol.18
, pp. 510-517
-
-
Pinto, C.1
Di Fabio, F.2
Siena, S.3
Cascinu, S.4
Rojas Llimpe, F.L.5
Ceccarelli, C.6
Mutri, V.7
Giannetta, L.8
Giaquinta, S.9
Funaioli, C.10
-
5
-
-
78649307699
-
Pharmacogenetics of irinotecan disposition and toxicity: A review
-
CrossRef PubMed
-
Fujita K, Sparreboom A. Pharmacogenetics of irinotecan disposition and toxicity: A review. Curr Clin Pharmacol. 2010; 5: 209-217. CrossRef PubMed
-
(2010)
Curr Clin Pharmacol.
, vol.5
, pp. 209-217
-
-
Fujita, K.1
Sparreboom, A.2
-
6
-
-
77954380404
-
Irinotecan pharmacogenomics
-
CrossRef PubMed
-
Marsh S, Hoskins JM. Irinotecan pharmacogenomics. Pharmacogenomics. 2010; 11: 1003-1010. CrossRef PubMed
-
(2010)
Pharmacogenomics.
, vol.11
, pp. 1003-1010
-
-
Marsh, S.1
Hoskins, J.M.2
-
7
-
-
77949629690
-
An overview of the recent progress in irinotecan pharmacogenetics
-
CrossRef PubMed
-
Fujiwara Y, Minami H. An overview of the recent progress in irinotecan pharmacogenetics. Pharmacogenomics. 2010; 11: 391-406. CrossRef PubMed
-
(2010)
Pharmacogenomics.
, vol.11
, pp. 391-406
-
-
Fujiwara, Y.1
Minami, H.2
-
8
-
-
2942527225
-
UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer
-
CrossRef PubMed
-
Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H, Hasegawa R, Kaniwa N, Sawada J, Komamura K, Ueno K, Kamakura S, Kitakaze M, Kitamura Y, Kamatani N, Minami H, Ohtsu A, Shirao K, Yoshida T, Saijo N. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther. 2004; 75: 501-515. CrossRef PubMed
-
(2004)
Clin Pharmacol Ther.
, vol.75
, pp. 501-515
-
-
Sai, K.1
Saeki, M.2
Saito, Y.3
Ozawa, S.4
Katori, N.5
Jinno, H.6
Hasegawa, R.7
Kaniwa, N.8
Sawada, J.9
Komamura, K.10
Ueno, K.11
Kamakura, S.12
Kitakaze, M.13
Kitamura, Y.14
Kamatani, N.15
Minami, H.16
Ohtsu, A.17
Shirao, K.18
Yoshida, T.19
Saijo, N.20
more..
-
9
-
-
77949755095
-
Phase i study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1∗28 polymorphism
-
CrossRef PubMed
-
Hazama S, Nagashima A, Kondo H, Yoshida S, Shimizu R, Araki A, Yoshino S, Okayama N, Hinoda Y, Oka M. Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1∗28 polymorphism. Cancer Sci. 2010; 101: 722-727. CrossRef PubMed
-
(2010)
Cancer Sci.
, vol.101
, pp. 722-727
-
-
Hazama, S.1
Nagashima, A.2
Kondo, H.3
Yoshida, S.4
Shimizu, R.5
Araki, A.6
Yoshino, S.7
Okayama, N.8
Hinoda, Y.9
Oka, M.10
-
10
-
-
79959815649
-
Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan tox icity
-
PubMed
-
Tanaka H, Saito K, Mino K, Izumi K, Harada M, Isobe H. [Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan tox icity]. Gan To Kagaku Ryoho. 2009; 36: 1505-1509. PubMed
-
(2009)
Gan to Kagaku Ryoho.
, vol.36
, pp. 1505-1509
-
-
Tanaka, H.1
Saito, K.2
Mino, K.3
Izumi, K.4
Harada, M.5
Isobe, H.6
-
11
-
-
0034671387
-
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis
-
PubMed
-
Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res. 2000; 60: 6921-6926. PubMed
-
(2000)
Cancer Res.
, vol.60
, pp. 6921-6926
-
-
Ando, Y.1
Saka, H.2
Ando, M.3
Sawa, T.4
Muro, K.5
Ueoka, H.6
Yokoyama, A.7
Saitoh, S.8
Shimokata, K.9
Hasegawa, Y.10
-
12
-
-
0032519431
-
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
-
CrossRef PubMed
-
Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998; 101: 847-854. CrossRef PubMed
-
(1998)
J Clin Invest.
, vol.101
, pp. 847-854
-
-
Iyer, L.1
King, C.D.2
Whitington, P.F.3
Green, M.D.4
Roy, S.K.5
Tephly, T.R.6
Coffman, B.L.7
Ratain, M.J.8
-
13
-
-
0034892379
-
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11
-
PubMed
-
Mathijssen RH, Van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001; 7: 2182-2194. PubMed
-
(2001)
Clin Cancer Res.
, vol.7
, pp. 2182-2194
-
-
Mathijssen, R.H.1
Van Alphen, R.J.2
Verweij, J.3
Loos, W.J.4
Nooter, K.5
Stoter, G.6
Sparreboom, A.7
-
14
-
-
0036025450
-
UGT1A1∗28 polymorphism as a determinant of irinotecan disposition and toxicity
-
CrossRef PubMed
-
Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ. UGT1A1∗28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2: 43-47. CrossRef PubMed
-
(2002)
Pharmacogenomics J.
, vol.2
, pp. 43-47
-
-
Iyer, L.1
Das, S.2
Janisch, L.3
Wen, M.4
Ramírez, J.5
Karrison, T.6
Fleming, G.F.7
Vokes, E.E.8
Schilsky, R.L.9
Ratain, M.J.10
-
15
-
-
34250202527
-
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: Roles of UGT1A1∗6 and∗28
-
CrossRef PubMed
-
Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: Roles of UGT1A1∗6 and∗28. Pharmacogenet Genomics. 2007; 17: 497-504. CrossRef PubMed
-
(2007)
Pharmacogenet Genomics.
, vol.17
, pp. 497-504
-
-
Minami, H.1
Sai, K.2
Saeki, M.3
Saito, Y.4
Ozawa, S.5
Suzuki, K.6
Kaniwa, N.7
Sawada, J.8
Hamaguchi, T.9
Yamamoto, N.10
Shirao, K.11
Yamada, Y.12
Ohmatsu, H.13
Kubota, K.14
Yoshida, T.15
Ohtsu, A.16
Saijo, N.17
-
16
-
-
34547788826
-
Role of UGT1A1∗6 UGT1A1∗28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients
-
Cross-Ref PubMed
-
Jada SR, Lim R, Wong CI, Shu X, Lee SC, Zhou Q, Goh BC, Chowbay B. Role of UGT1A1∗6, UGT1A1∗28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci. 2007; 98: 1461-1467. Cross-Ref PubMed
-
(2007)
Cancer Sci.
, vol.98
, pp. 1461-1467
-
-
Jada, S.R.1
Lim, R.2
Wong, C.I.3
Shu, X.4
Lee, S.C.5
Zhou, Q.6
Goh, B.C.7
Chowbay, B.8
-
17
-
-
0032718482
-
Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates
-
CrossRef PubMed
-
Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics. 1999; 9: 591-599. CrossRef PubMed
-
(1999)
Pharmacogenetics.
, vol.9
, pp. 591-599
-
-
Hall, D.1
Ybazeta, G.2
Destro-Bisol, G.3
Petzl-Erler, M.L.4
Di Rienzo, A.5
-
18
-
-
79960535705
-
Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs
-
CrossRef PubMed
-
Sai K, Saito Y. Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs. Expert Opin Drug Metab Toxicol. 2011; 7: 967-988. CrossRef PubMed
-
(2011)
Expert Opin Drug Metab Toxicol.
, vol.7
, pp. 967-988
-
-
Sai, K.1
Saito, Y.2
-
19
-
-
73449111242
-
UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer
-
CrossRef PubMed
-
Schulz C, Heinemann V, Schalhorn A, Moosmann N, Zwingers T, Boeck S, Giessen C, Stemmler HJ. UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. World J Gastroenterol. 2009; 15: 5058-5066. CrossRef PubMed
-
(2009)
World J Gastroenterol.
, vol.15
, pp. 5058-5066
-
-
Schulz, C.1
Heinemann, V.2
Schalhorn, A.3
Moosmann, N.4
Zwingers, T.5
Boeck, S.6
Giessen, C.7
Stemmler, H.J.8
-
20
-
-
79959750597
-
UGT1A1∗1/∗28 and∗1/∗6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer
-
CrossRef PubMed
-
Sunakawa Y, Ichikawa W, Fujita K, Nagashima F, Ishida H, Yamashita K, Mizuno K, Miwa K, Kawara K, Akiyama Y, Araki K, Yamamoto W, Miya T, Narabayashi M, Ando Y, Hirose T, Saji S, Sasaki Y. UGT1A1∗1/∗28 and∗1/∗6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2011; 68: 279-284. CrossRef PubMed
-
(2011)
Cancer Chemother Pharmacol.
, vol.68
, pp. 279-284
-
-
Sunakawa, Y.1
Ichikawa, W.2
Fujita, K.3
Nagashima, F.4
Ishida, H.5
Yamashita, K.6
Mizuno, K.7
Miwa, K.8
Kawara, K.9
Akiyama, Y.10
Araki, K.11
Yamamoto, W.12
Miya, T.13
Narabayashi, M.14
Ando, Y.15
Hirose, T.16
Saji, S.17
Sasaki, Y.18
-
21
-
-
79959965073
-
Clinical implications of UGT1A1∗28 genotype testing in colorectal cancer patients
-
CrossRef PubMed
-
Shulman K, Cohen I, Barnett-Griness O, Kuten A, Gruber SB, Lejbkowicz F, Rennert G. Clinical implications of UGT1A1∗28 genotype testing in colorectal cancer patients. Cancer. 2011; 117: 3156-3162. CrossRef PubMed
-
(2011)
Cancer.
, vol.117
, pp. 3156-3162
-
-
Shulman, K.1
Cohen, I.2
Barnett-Griness, O.3
Kuten, A.4
Gruber, S.B.5
Lejbkowicz, F.6
Rennert, G.7
-
22
-
-
12144286615
-
Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan
-
CrossRef PubMed
-
Sai K, Kaniwa N, Itoda M, Saito Y, Hasegawa R, Komamura K, Ueno K, Kamakura S, Kitakaze M, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Kitamura Y, Kamatani N, Ozawa S, Sawada J. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics. 2003; 13: 741-757. CrossRef PubMed
-
(2003)
Pharmacogenetics.
, vol.13
, pp. 741-757
-
-
Sai, K.1
Kaniwa, N.2
Itoda, M.3
Saito, Y.4
Hasegawa, R.5
Komamura, K.6
Ueno, K.7
Kamakura, S.8
Kitakaze, M.9
Shirao, K.10
Minami, H.11
Ohtsu, A.12
Yoshida, T.13
Saijo, N.14
Kitamura, Y.15
Kamatani, N.16
Ozawa, S.17
Sawada, J.18
-
23
-
-
79151469394
-
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
-
CrossRef PubMed
-
Glimelius B, Garmo H, Berglund A, Fredriksson LA, Berglund M, Kohnke H, Byström P, Sørbye H, Wadelius M. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J. 2011; 11: 61-71. CrossRef PubMed
-
(2011)
Pharmacogenomics J.
, vol.11
, pp. 61-71
-
-
Glimelius, B.1
Garmo, H.2
Berglund, A.3
Fredriksson, L.A.4
Berglund, M.5
Kohnke, H.6
Byström, P.7
Sørbye, H.8
Wadelius, M.9
-
24
-
-
34250825286
-
Associations of ABCB1 ABCC2 and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer
-
Cross-Ref PubMed
-
Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, Lee JE, Lee DH, Kim HT, Lee JS. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer. 2007; 110: 138-147. Cross-Ref PubMed
-
(2007)
Cancer.
, vol.110
, pp. 138-147
-
-
Han, J.Y.1
Lim, H.S.2
Yoo, Y.K.3
Shin, E.S.4
Park, Y.H.5
Lee, S.Y.6
Lee, J.E.7
Lee, D.H.8
Kim, H.T.9
Lee, J.S.10
-
25
-
-
65349181626
-
UGT1A1∗6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients
-
CrossRef PubMed
-
Onoue M, Terada T, Kobayashi M, Katsura T, Matsumoto S, Yanagihara K, Nishimura T, Kanai M, Teramukai S, Shimizu A, Fukushima M, Inui K. UGT1A1∗6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol. 2009; 14: 136-142. CrossRef PubMed
-
(2009)
Int J Clin Oncol.
, vol.14
, pp. 136-142
-
-
Onoue, M.1
Terada, T.2
Kobayashi, M.3
Katsura, T.4
Matsumoto, S.5
Yanagihara, K.6
Nishimura, T.7
Kanai, M.8
Teramukai, S.9
Shimizu, A.10
Fukushima, M.11
Inui, K.12
-
26
-
-
42449139713
-
UGT1A1∗28 polymorphism predicts irinotecaninduced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma
-
CrossRef PubMed
-
Liu CY, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS. UGT1A1∗28 polymorphism predicts irinotecaninduced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer. 2008; 112: 1932-1940. CrossRef PubMed
-
(2008)
Cancer.
, vol.112
, pp. 1932-1940
-
-
Liu, C.Y.1
Chen, P.M.2
Chiou, T.J.3
Liu, J.H.4
Lin, J.K.5
Lin, T.C.6
Chen, W.S.7
Jiang, J.K.8
Wang, H.S.9
Wang, W.S.10
-
27
-
-
79953737378
-
Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms
-
Cross-Ref PubMed
-
Okuyama Y, Hazama S, Nozawa H, Kobayashi M, Takahashi K, Fujikawa K, Kato T, Nagata N, Kimura H, Oba K, Sakamoto J, Mishima H. Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms. Jpn J Clin Oncol. 2011; 41: 477-482. Cross-Ref PubMed
-
(2011)
Jpn J Clin Oncol.
, vol.41
, pp. 477-482
-
-
Okuyama, Y.1
Hazama, S.2
Nozawa, H.3
Kobayashi, M.4
Takahashi, K.5
Fujikawa, K.6
Kato, T.7
Nagata, N.8
Kimura, H.9
Oba, K.10
Sakamoto, J.11
Mishima, H.12
-
28
-
-
84877737684
-
UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients
-
CrossRef PubMed
-
Gao J, Zhou J, Li Y, Lu M, Jia R, Shen L. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients. Med Oncol. 2013; 30: 604. CrossRef PubMed
-
(2013)
Med Oncol.
, vol.30
, pp. 604
-
-
Gao, J.1
Zhou, J.2
Li, Y.3
Lu, M.4
Jia, R.5
Shen, L.6
-
29
-
-
77953289476
-
Dose-dependent association between UGT1A1∗28 polymorphism and irinotecan-induced diarrhoea: A meta-analysis
-
CrossRef PubMed
-
Hu ZY, Yu Q, Zhao YS. Dose-dependent association between UGT1A1∗28 polymorphism and irinotecan-induced diarrhoea: A meta-analysis. Eur J Cancer. 2010; 46: 1856-1865. CrossRef PubMed
-
(2010)
Eur J Cancer.
, vol.46
, pp. 1856-1865
-
-
Hu, Z.Y.1
Yu, Q.2
Zhao, Y.S.3
-
30
-
-
34748857912
-
Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations
-
Cross-Ref PubMed
-
Zhang A, Xing Q, Qin S, Du J, Wang L, Yu L, Li X, Xu L, Xu M, Feng G, He L. Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations. Pharmacogenomics J. 2007; 7: 333-338. Cross-Ref PubMed
-
(2007)
Pharmacogenomics J.
, vol.7
, pp. 333-338
-
-
Zhang, A.1
Xing, Q.2
Qin, S.3
Du, J.4
Wang, L.5
Yu, L.6
Li, X.7
Xu, L.8
Xu, M.9
Feng, G.10
He, L.11
-
31
-
-
84898058478
-
Associations between UGT1A1∗6 or UGT1A1∗6/∗28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients
-
CrossRef PubMed
-
Han FF, Guo CL, Yu D, Zhu J, Gong LL, Li GR, Lv YL, Liu H, An GY, Liu LH. Associations between UGT1A1∗6 or UGT1A1∗6/∗28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients. Cancer Chemother Pharmacol. 2014; 73: 779-788. CrossRef PubMed
-
(2014)
Cancer Chemother Pharmacol.
, vol.73
, pp. 779-788
-
-
Han, F.F.1
Guo, C.L.2
Yu, D.3
Zhu, J.4
Gong, L.L.5
Li, G.R.6
Lv, Y.L.7
Liu, H.8
An, G.Y.9
Liu, L.H.10
-
32
-
-
84872287715
-
Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer
-
CrossRef PubMed
-
Takahara N, Nakai Y, Isayama H, Sasaki T, Satoh Y, Takai D, Hamada T, Uchino R, Mizuno S, Miya bayashi K, Mohri D, Kawakubo K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tada M, Yatomi Y, Koike K. Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer. Cancer Chemother Pharmacol. 2013; 71: 85-92. CrossRef PubMed
-
(2013)
Cancer Chemother Pharmacol.
, vol.71
, pp. 85-92
-
-
Takahara, N.1
Nakai, Y.2
Isayama, H.3
Sasaki, T.4
Satoh, Y.5
Takai, D.6
Hamada, T.7
Uchino, R.8
Mizuno, S.9
Miyabayashi, K.10
Mohri, D.11
Kawakubo, K.12
Kogure, H.13
Yamamoto, N.14
Sasahira, N.15
Hirano, K.16
Ijichi, H.17
Tada, M.18
Yatomi, Y.19
Koike, K.20
more..
-
33
-
-
84896051392
-
UGT1A1∗6 polymorphisms are correlated with irinotecan-induced toxicity: A system review and meta-analysis in Asians
-
CrossRef PubMed
-
Cheng L, Li M, Hu J, Ren W, Xie L, Sun ZP, Liu BR, Xu GX, Dong XL, Qian XP. UGT1A1∗6 polymorphisms are correlated with irinotecan-induced toxicity: A system review and meta-analysis in Asians. Cancer Chemother Pharmacol. 2014; 73: 551-560. CrossRef PubMed
-
(2014)
Cancer Chemother Pharmacol.
, vol.73
, pp. 551-560
-
-
Cheng, L.1
Li, M.2
Hu, J.3
Ren, W.4
Xie, L.5
Sun, Z.P.6
Liu, B.R.7
Xu, G.X.8
Dong, X.L.9
Qian, X.P.10
-
34
-
-
84863805445
-
The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens
-
CrossRef PubMed
-
Lamas MJ, Duran G, Balboa E, Bernardez B, Candamio S, Vidal Y, Mosquera A, Giraldez JM, Lopez R, Carracedo A, Barros F. The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens. Cancer Chemother Pharmacol. 2012; 69: 1591-1599. CrossRef PubMed
-
(2012)
Cancer Chemother Pharmacol.
, vol.69
, pp. 1591-1599
-
-
Lamas, M.J.1
Duran, G.2
Balboa, E.3
Bernardez, B.4
Candamio, S.5
Vidal, Y.6
Mosquera, A.7
Giraldez, J.M.8
Lopez, R.9
Carracedo, A.10
Barros, F.11
-
35
-
-
84897383948
-
Association of UGT1A1∗28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: A meta-analysis in Caucasians
-
CrossRef PubMed
-
Liu X, Cheng D, Kuang Q, Liu G, Xu W. Association of UGT1A1∗28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: A meta-analysis in Caucasians. Pharmacogenomics J. 2014; 14: 120-129. CrossRef PubMed
-
(2014)
Pharmacogenomics J.
, vol.14
, pp. 120-129
-
-
Liu, X.1
Cheng, D.2
Kuang, Q.3
Liu, G.4
Xu, W.5
-
36
-
-
0037229942
-
Role of P-glycoprotein in pharmacokinetics: Clinical implications
-
CrossRef PubMed
-
Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: Clinical implications. Clin Pharmacokinet. 2003; 42: 59-98. CrossRef PubMed
-
(2003)
Clin Pharmacokinet.
, vol.42
, pp. 59-98
-
-
Lin, J.H.1
Yamazaki, M.2
-
37
-
-
84878637878
-
Differential toxicity biomarkers for irinotecan-and oxaliplatin-containing chemotherapy in colorectal cancer
-
CrossRef PubMed
-
Cortejoso L, García MI, García-Alfonso P, González-Haba E, Escolar F, Sanjurjo M, López-Fernández LA. Differential toxicity biomarkers for irinotecan-and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemother Pharmacol. 2013; 71: 1463-1472. CrossRef PubMed
-
(2013)
Cancer Chemother Pharmacol.
, vol.71
, pp. 1463-1472
-
-
Cortejoso, L.1
García, M.I.2
García-Alfonso, P.3
González-Haba, E.4
Escolar, F.5
Sanjurjo, M.6
López-Fernández, L.A.7
-
38
-
-
84865342457
-
Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients
-
CrossRef PubMed
-
Cortejoso L, López-Fernández LA. Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients. Pharmacogenomics. 2012; 13: 1173-1191. CrossRef PubMed
-
(2012)
Pharmacogenomics.
, vol.13
, pp. 1173-1191
-
-
Cortejoso, L.1
López-Fernández, L.A.2
|